📊 PTGX Key Takeaways
Is Protagonist Therapeutics, Inc (PTGX) a Good Investment?
Protagonist Therapeutics faces severe operational distress with revenue collapsing 89% YoY while burning $48.9M in operating cash annually. Despite a strong balance sheet with $193.7M in cash, deteriorating fundamentals—negative operating margins, persistent cash burn, and minimal returns on assets (0.5%)—indicate the core business is in substantial decline. The company's cash runway of ~4 years provides temporary stability but offers insufficient time to reverse the dramatic top-line contraction without credible turnaround evidence.
Why Buy Protagonist Therapeutics, Inc Stock? PTGX Key Strengths
- Strong balance sheet with $655.5M stockholders' equity and minimal debt ($9.8M)
- Substantial cash reserves of $193.7M providing operational runway
- Exceptional liquidity position (17.76x current ratio) enabling survival through restructuring
PTGX Stock Risks: Protagonist Therapeutics, Inc Investment Risks
- Catastrophic revenue decline of 89.4% YoY signals loss of key product, partnership termination, or clinical failure
- Negative operating cash flow of -$48.9M with no clear path to profitability in disclosed metrics
- Operating margin of -6.5% combined with minimal ROE (0.6%) and ROA (0.5%) indicates fundamental business model stress
- Cash depletion timeline (~4 years at current burn rate) creates existential pressure without revenue stabilization
Key Metrics to Watch
- Quarterly revenue trend and stabilization signals
- Operating cash flow inflection point toward positive territory
- Gross margin and operating leverage recovery metrics
- Cash burn rate trajectory and runway extension milestones
Protagonist Therapeutics, Inc (PTGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.76x current ratio provides a solid financial cushion.
PTGX Profit Margin, ROE & Profitability Analysis
PTGX vs Healthcare Sector: How Protagonist Therapeutics, Inc Compares
How Protagonist Therapeutics, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Protagonist Therapeutics, Inc Stock Overvalued? PTGX Valuation Analysis 2026
Based on fundamental analysis, Protagonist Therapeutics, Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Protagonist Therapeutics, Inc Balance Sheet: PTGX Debt, Cash & Liquidity
PTGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Protagonist Therapeutics, Inc's revenue has grown significantly by 1,418% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.39 indicates the company is currently unprofitable.
PTGX Revenue Growth, EPS Growth & YoY Performance
PTGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $28.3M | $3.8M | $0.05 |
| Q3 2025 | $4.7M | -$33.2M | $-0.54 |
| Q2 2025 | $4.2M | -$30.6M | $-0.50 |
| Q1 2025 | $28.3M | -$11.7M | $-0.19 |
| Q3 2024 | N/A | -$33.2M | $-0.54 |
| Q2 2024 | N/A | -$30.6M | $-0.50 |
| Q1 2024 | N/A | -$33.7M | $-0.67 |
| Q3 2023 | N/A | -$31.2M | $-0.58 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Protagonist Therapeutics, Inc Dividends, Buybacks & Capital Allocation
PTGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Protagonist Therapeutics, Inc (CIK: 0001377121)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PTGX
What is the AI rating for PTGX?
Protagonist Therapeutics, Inc (PTGX) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PTGX's key strengths?
Claude: Strong balance sheet with $655.5M stockholders' equity and minimal debt ($9.8M). Substantial cash reserves of $193.7M providing operational runway.
What are the risks of investing in PTGX?
Claude: Catastrophic revenue decline of 89.4% YoY signals loss of key product, partnership termination, or clinical failure. Negative operating cash flow of -$48.9M with no clear path to profitability in disclosed metrics.
What is PTGX's revenue and growth?
Protagonist Therapeutics, Inc reported revenue of $56.4M.
Does PTGX pay dividends?
Protagonist Therapeutics, Inc does not currently pay dividends.
Where can I find PTGX SEC filings?
Official SEC filings for Protagonist Therapeutics, Inc (CIK: 0001377121) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PTGX's EPS?
Protagonist Therapeutics, Inc has a diluted EPS of $0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PTGX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Protagonist Therapeutics, Inc has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PTGX stock overvalued or undervalued?
Valuation metrics for PTGX: ROE of 0.6% (sector avg: 15%), net margin of 6.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PTGX stock in 2026?
Our dual AI analysis gives Protagonist Therapeutics, Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PTGX's free cash flow?
Protagonist Therapeutics, Inc's operating cash flow is $-48.9M, with capital expenditures of $215.0K. FCF margin is -87.2%.
How does PTGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.7% (avg: 12%), ROE 0.6% (avg: 15%), current ratio 17.76 (avg: 2).